These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25935769)

  • 1. Pembrolizumab shows promise in lung cancer.
    Cleghorn S
    Lancet Respir Med; 2015 Jun; 3(6):429. PubMed ID: 25935769
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab Shows Promise for NSCLC.
    Cancer Discov; 2015 Jun; 5(6):572. PubMed ID: 25895920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab Outperforms Docetaxel for NSCLC.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
    [No Abstract]   [Full Text] [Related]  

  • 7. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
    Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE
    Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178
    [No Abstract]   [Full Text] [Related]  

  • 8. [The TULUNG clinical registry].
    Spelda S; Skřičková J; Bortlíček Z; Hejduk K; Pešek M; Zatloukal P; Kolek V; Salajka F; Koubková L; Tomíšková M; Grygárková Y; Havel L; Hrnčiarik M; Zemanová M; Sixtová D; Roubec J; Coupková H; Košatová K
    Klin Onkol; 2012; 25(5):383-4. PubMed ID: 23102201
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bevacizumab in thoracic oncology: results and practical aspects].
    Dansin É; Cousin S; Lauridant G; Mennecier B
    Rev Pneumol Clin; 2013 Jun; 69(3):159-69. PubMed ID: 23597632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-oncology drugs jostle for first-line setting.
    Mullard A
    Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role?
    Kalemkerian G
    J Clin Oncol; 2005 Feb; 23(6):1325-6; author reply 1326-7. PubMed ID: 15718337
    [No Abstract]   [Full Text] [Related]  

  • 12. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Mar; 6(5):267-8. PubMed ID: 15845175
    [No Abstract]   [Full Text] [Related]  

  • 14. Advanced non-small cell lung cancer - Treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619
    [No Abstract]   [Full Text] [Related]  

  • 15. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
    Mok TSK; Loong HH
    Lancet; 2016 Apr; 387(10027):1488-1490. PubMed ID: 26712085
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
    Girard N
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.
    Rosell R
    J Clin Oncol; 2004 Apr; 22(7):1171-3. PubMed ID: 14981109
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
    Mueller E
    Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
    J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in lung cancer.
    Wang Y; Deng G; Liu X; Cho WC
    Expert Opin Biol Ther; 2013 Feb; 13(2):209-26. PubMed ID: 23240766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.